Key result
Myxopapillary ependymoma subtype MPE-A is linked to ~158% higher relapse risk than MPE-B.
Why the study?
The underlying molecular biology of myxopapillary ependymoma is poorly understood, and markers to reliably predict patient clinical outcomes remain unknown.
Cohort (n=185)
Absolute Event Rate: 85% vs 33%
p-value: p=3.4e-06
DNA methylation profiling identifies two distinct molecular subtypes of myxopapillary ependymoma (MPE-A and MPE-B) with significantly different progression-free survival, which may guide future surveillance and treatment.
No takes yet. Share an insight, caveat, or question.
May support risk-adapted surveillance; hypothesis-generating and requires prospective validation before guiding management.
Bockmayr et al. (2022) conducted a cohort in Myxopapillary ependymoma (n=185). MPE-A molecular subtype vs. MPE-B molecular subtype was evaluated on Relapse within 10 years (p=3.4e-06). DNA methylation profiling of myxopapillary ependymomas identified two distinct subtypes, with MPE-A having a significantly higher 10-year relapse rate compared to MPE-B (85% vs 33%, P=3.4e-06).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: